Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 210 East Grand Avenue SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://allogene.com |
IR: | See website |
Key People | ||
Arie S. Belldegrun Executive Chairman of the Board | David Chang President, Chief Executive Officer, Co-Founder, Director | Geoffrey M. Parker Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer |
Timothy L. Moore Executive Vice President, Chief Technical Officer | Zachary Roberts Executive Vice President - Research and Development, Chief Medical Officer | Earl Martin Douglas General Counsel |
Business Overview |
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647. |
Financial Overview |
For the fiscal year ended 31 December 2023, Allogene Therapeutics Inc revenues decreased 39% to $95K. Net loss decreased 4% to $327.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Personnel decrease of 13% to $112.5M (expense), Interest and other income, net increase from $4.6M to $18.3M (income). |
Employees: | 232 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $110.24M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.09M as of Mar 31, 2024 |
EBITDA (TTM): | -$270.66M as of Mar 31, 2024 |
Net annual income (TTM): | -$292.30M as of Mar 31, 2024 |
Free cash flow (TTM): | -$227.48M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 170,723,100 as of Apr 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |